Tempest Therapeutics

TPST · NASDAQ

$0.5762−$0.0239 (−3.98%)TodayMarket closed · Oct 20, 7:54 PM ET

Prev close $0.6001

TPST analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $7.14 (+1139.2% upside)

Low: $7.07
Now: $0.5762
High: $7.35

Upgrades and downgrades

The latest rating actions, newest first

TPST analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 24, 2026	Maintains	Buy	$11.00 → $7.00	40%
HC Wainwright & Co.	Jan 22, 2026	Upgrade	Neutral → Buy	$11.00	40%

The case for and against

Updated Mar 27, 2025

Bull case

Tempest Therapeutics has demonstrated a promising outlook, bolstered by recent positive updates from Roche/Genentech's MORPHEUS-Liver study, indicating that the combination of their product TPST-1120 and existing therapies exhibits superior clinical benefits over the standard of care. The company benefits from a drug supply agreement with Roche, which will not only provide atezolizumab for upcoming pivotal studies but also result in significant cost savings. Furthermore, the recent clinical data suggests a 35% reduction in the risk of death and a six-month improvement in median overall survival compared to the standard of care, highlighting the potential for enhanced market penetration and increased valuation as the company progresses.

Bear case

Tempest Therapeutics Inc faces a negative outlook primarily due to concerns surrounding its financial stability and ongoing development costs, particularly following a recent Phase 2 update. The company’s current cash balance is considered insufficient to support the anticipated expenses associated with advancing its clinical-stage product candidates, TPST-1120 and TPST-1495, through further clinical trials. Additionally, challenges such as the potential for failed clinical trials, difficulties in securing necessary funding, and the possibility of dilutive capital raises contribute to the overall uncertainty regarding the company’s future prospects and commercial success.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.